Biofrontera Reports Positive Phase 3 Results for Ameluz® PDT, Plans sNDA Submission
BFRI sits 90% above its 52-week low of $0.536.
Summary
Biofrontera Inc. reported positive Phase 3 clinical trial results for Ameluz® PDT, meeting its primary endpoint with high statistical significance and indicating a significant expansion of its potential market. The company plans to submit an sNDA in Q3 2026.
Key Events · Product Development and Regulatory · BFRI
-
Positive Phase 3 Clinical Trial Results
Biofrontera Inc. announced positive top-line results from its Phase 3 study of Ameluz® PDT for actinic keratoses on the extremities, neck, and trunk.
-
Met Primary Endpoint with Statistical Significance
The study met its primary endpoint, showing highly statistically significant superiority for Ameluz® PDT versus vehicle gel (p<0.0003) in achieving complete clearance of all treated AK lesions.
-
Expanded Market Potential
These data support Ameluz®'s potential to treat broader, high-burden AK fields beyond the face and scalp, significantly expanding its addressable market.
-
Planned sNDA Submission
Based on these positive results, Biofrontera plans to submit a supplemental New Drug Application (sNDA) to the U.S. FDA in the third quarter of 2026.
Analysis · BFRI · Life Sciences
Biofrontera Inc. announced highly positive Phase 3 clinical trial results for its Ameluz® PDT treatment, demonstrating statistically significant superiority over vehicle gel for actinic keratoses on the extremities, neck, and trunk. This successful trial expands the potential addressable market for Ameluz® beyond its current indication for the face and scalp, which is a critical development for the company. The planned submission of a supplemental New Drug Application (sNDA) in Q3 2026, if approved, could significantly boost revenue and market position. This positive news follows a recent Nasdaq delisting notice, providing a potential catalyst to address compliance issues and build on the preliminary record revenues reported earlier this year.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BFRI was trading at $1.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.6M. The 52-week trading range was $0.54 to $1.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.